Contact the Editorial Desk

Editorial correspondence

Peptide Rejuvination welcomes correspondence on the research record: a citation quoted inaccurately, a newly published case report or trial on GLOW's constituents or on Melanotan II, or a regulatory update that changes an approval or prohibited-substance status. This is the most useful class of message this desk receives, and each is read carefully.

The most actionable submissions specify the page in question, the exact passage being corrected or challenged, and a supporting reference — a DOI or PubMed identifier wherever possible — so the proposed change can be verified against its source before anything is edited.

Editorial mailbox: editors@peptiderejuvination.com

What this desk cannot do

Peptide Rejuvination is a literature digest, not a clinical, dermatological, or cosmetic service, and it cannot: advise on or recommend human use of GLOW, Melanotan II, or any of their constituents; suggest a dose, schedule, or route of administration for any individual; evaluate whether a cited finding applies to a specific person's skin, health, or situation; or sell, source, recommend, or help locate a supplier for any compound. Because TB-500 sits under WADA's Prohibited List, this desk also cannot advise athletes subject to anti-doping testing on how to use GLOW.

Readers seeking clinical or dermatological guidance should consult a licensed provider in their jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.